Cognitive function prior to systemic therapy and subsequent well‐being in older breast cancer survivors: Longitudinal findings from the Thinking and Living with Cancer Studyagingbreast cancercancercancer survivorscognitive functiononcologyquality of life...
However, the treatment options have been historically limited, especially after prior systemic therapy. Immunotherapy has been changing the treatment landscape of endometrial cancer. Several anti-programmed death 1 (PD-1) or its ligand (PD-L1) inhibitors (pembrolizumab, dostarlimab, avelumab, and...
antiangiogeniccombination therapytargeted therapytoxicitySeveral novel therapies have been approved recently in advanced renal cell carcinoma (RCC). These agents ... J Sosman,I Puzanov - 《Cancer》 被引量: 157发表: 2010年 Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatme...
*p \ 0.001 compared with placebo lymphoma, leukemia, nonmelanoma skin cancer, or melanoma. 4 Discussion This analysis confirmed that adalimumab is efficacious for the treatment of moderate to severe psoriasis in patients who have received prior systemic therapy, including patients who did not respond ...
In cohort 2, patients were required to have HER2-negative breast cancer, defined as HER2 immunohistochemistry (IHC) score 0-1 or FISH negative; had developed new lesions or progressed after radiation therapy and/or surgery for the treatment of intracranial lesion; with at least one measurable (...
FULL PAPER British Journal of Cancer (2014) 110, 2821–2828 | doi: 10.1038/bjc.2014.244 Keywords: axitinib; sorafenib; renal cell carcinoma; prior therapy; VEGF receptor inhibitor Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III ...
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database Lancet Oncol, 17 (12) (2016), pp. 1709-1719 View ...
To evaluate this relationship in greater detail, we analyzed the incidence of COVID-19 compared ICIs with other anti-cancer treatments including chemotherapy, targeted therapy. Prior exposure to ICIs did not significantly reduce the incidence of COVID-19 infection in cancer patients compared with ...
B Interference with odronextamab from other anti-CD20 therapeutic antibodies (e.g., rituximab) from prior disease treatment generates a false-positive NAb result. Assay interference can be mitigated with an anti-idiotypic antibody against the interfering therapy. ...
After initial mosunetuzumab treatment, 34/90 (37.8%) patients had received a new anti-lymphoma therapy, including 33/90 (36.7%) patients who received a new systemic treatment (8/33 [24.2%] of these patients received chimeric antigen rec...